drugset / Trial / NCT01238952
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-11
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |